BHVN
Biohaven Pharmaceutical Holding Co Ltd
NYSE: BHVN · HEALTHCARE · BIOTECHNOLOGY
$9.59
+4.24% today
Updated 2026-04-30
Market cap
$1.38B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-6.86
Dividend yield
—
52W range
$7 – $24
Volume
2.2M
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $462.51M | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | -100.0% | — | — | — |
| Cost of revenue | — | — | $72000.00 | $1.39M | $1.39M | $3.37M | $3.92M | $4.14M |
| Gross profit | — | — | $-72000.00 | $370.85M | $-1.39M | $-3.37M | $-3.92M | $-4.14M |
| Gross margin | — | — | — | 80.2% | — | — | — | — |
| R&D | — | $344.67M | $98.46M | $181.49M | $437.07M | $373.28M | $795.87M | $635.07M |
| SG&A | — | $134.45M | $16.05M | $37.41M | $130.86M | $62.77M | $89.24M | $106.17M |
| Operating income | — | $-479.12M | $-114.51M | $-218.90M | $-567.93M | $-436.05M | $-885.11M | $-745.38M |
| Operating margin | — | — | — | -47.3% | — | — | — | — |
| EBITDA | — | $-479.12M | $-114.43M | $-217.51M | $-566.55M | $-429.14M | $-877.26M | $-727.46M |
| EBITDA margin | — | — | — | -47.0% | — | — | — | — |
| EBIT | — | $-479.12M | $-114.51M | $-218.90M | $-567.93M | $-436.05M | $-885.11M | $-737.38M |
| Interest expense | — | $12.71M | — | $41.55M | $1.39M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | — | $-528.80M | $-118.67M | $-213.80M | $-570.28M | $-408.17M | $-846.42M | $-738.82M |
| Net income growth (YoY) | — | — | +77.6% | -80.2% | -166.7% | +28.4% | -107.4% | +12.7% |
| Profit margin | — | — | — | -46.2% | — | — | — | — |